Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589 (‘589 Patent) issued on November 22, 2016, entitled “Chimeric Vaccines.”
The health IT startup received an investment from KiwiVenture Partners II earlier this month. The terms of the infusion from the New York-based venture firm were not disclosed.
A $65 million building was dedicated Monday afternoon at the East Baltimore Development Inc. project that will include a business incubator, research space and a Starbucks job training site.
The Institute of Human Virology at the University of Maryland School of Medicine will receive $138 million in federal funds that will support the work of the newly created Center for International Health, Education and Biosecurity to build programs in Africa to combat HIV/AIDS.
Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages. In fact, the first three quarters of 2016 alone are already higher than the annual rate of venture investing in all but two years since 2002.
House and Senate health committee leaders have released the final “21st Century Cures” bill and announced that the House of Representatives will vote Wednesday on a $6.3 Billion landmark medical innovation package that will accelerate the discovery, development, and delivery of new cures and treatments and provide new funding for the National Institutes of Health and Food and Drug Administration. The leaders said the House would also vote Wednesday to include in the Cures bill legislation that updates major mental health programs for the first time in a decade. The new funding includes $1 billion in state grants to fight opioid abuse.
The University of Virginia Health System has named its first-ever Chief Innovation Officer, a position that’s expected to bridge the gap between research and treatment.
UVA is home to revolutionizing research and technology but newly-hired CIO Jeff Keller will facilitate in putting the research to use.
House and Senate leaders announced late Friday night that they had finally hammered out a deal on landmark legislation designed to speed federal approval of new drugs and devices and boost funding of medical research.
But what Republican lawmakers call the “final” version of the 21st Century Cures Act is actually still in negotiation with Senate Democrats, a senior Democratic aide told STAT on Sunday.
The 2017 FLC Awards is now open for nominations. One of the most coveted honors in the technology transfer field, the FLC Awards have been presented to over 200 federal laboratories since their inception in 1984. Many of our winning technology transfer efforts have gone on to become products and devices that are indispensable in our daily lives, including:
The i6 Challenge award sets aim on enhancing Long Island Bioscience Ecosystem
The Center for Biotechnology at Stony Brook University has announced that is has received a three-year, $500,000 U.S. Department of Commerce i6 Challenge Investment. The award will support the Center for Biotechnology’s (CFB) efforts to bolster the regional bioscience ecosystem by supporting a formal mentorship program, as well as a critical NIH-focused SBIR/STTR training and application development program which will assist in capital formation and launching new companies.
Tuesday, November 29th | 10:00am – 12:00 pm Rockville Innovation Center, 155 Gibbs Street, Rockville, MD 20850
Hosted by BioHealth Innovation
You’ve probably heard about the Cloud, Big Data and Machine Learning, but where does the hype end and the true value of these technologies begin? Can, or should, your business leverage these technologies? Mark Weston and Matt Puglisi from Netrias LLC (www.netrias.com) will describe the current state of the art for Cloud computing, Big Data and Machine Learning to help you better leverage these technologies for your business.
Mark Weston, Chief Software Architect, is a software engineer with extensive experience in applying distributed database technologies to problems at scale. Matt Puglisi, Chief Executive Officer is a seasoned leader with successful experience as a technology company executive, a leader of research and development efforts, government service, and military service
Please RSVP by November 22nd to Joyce Debrowski (jdebrowski@scheerpartners.com | (301) 279-2222). The event is open to the first 30 registrants only.
International Trade – The Basics for Bio & Technology Companies
Attend this lunch-and-learn event to hear global industry experts discuss how Maryland companies can leverage resources to fund and market their international ambitions. Hear from one local company who has successfully taken advantage of these tools.
WHO SHOULD ATTEND: Existing companies and startups in the life sciences and health technology industries
PANELISTS:
Jessica Reynolds, Regional Manager for Europe and Africa at Maryland Department of Commerce’s Office of International Investment and Trade
Barry Bogage, Executive Director of Maryland Israel Development Center
Carla Menendez McManus, Commercial Officer at U.S. Export Assistance Center
Dr. Hyacinth Ntchobo, Founder and CEO of MagBio Genomics
The Showcase is a fantastic networking event and expo. It will feature booths for Israeli companies in Maryland, as well as Maryland companies who have business relationships with Israeli companies. In addition, the program will feature insight from the heart of the U.S.-Israel business world from one of its foremost leaders, Zur Feldman. This is your chance to meet leaders from Israeli hi-tech, life sciences, cyber and homeland security companies and others operating in Maryland. This is a great opportunity for local companies, investors and organizations who want to explore or expand their involvement in the robust U.S.-Israel business ecosystem and for all to learn about that ecosystem.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
